Toreforant Explained
Toreforant (JNJ-38518168) is an orally-dosed selective antagonist of the histamine H4 receptor that has been studied for various health conditions. It is the successor of a number of H4-selective compounds developed by Johnson & Johnson.[1] Phase IIa clinical trials completed as recently as November 2018 continue to suggest that toreforant is safe.[2]
As of the end of 2020, there is no regulator-approved H4 antagonist. In U.S. Phase II clinical trials, toreforant, by itself, did not show efficacy against eosinophilic asthma. The drug did show at least partial efficacy against rheumatoid arthritis in patients who were nonresponsive to methotrexate.[3] As the H4 receptor is widely implicated in the regulation of inflammatory states, the potential uses for an H4 antagonist remain significant.[4] [5] [6]
See also
Notes and References
- Book: Thurmond RL, Venable J, Savall B, La D, Snook S, Dunford PJ, Edwards JP . Histamine and Histamine Receptors in Health and Disease . 2017 . Clinical Development of Histamine H4 Receptor Antagonists . Handbook of Experimental Pharmacology . 241 . 301–320 . 28233185 . 10.1007/164_2016_130 . 978-3-319-58192-7 .
- Kollmeier AP, Barnathan ES, O'Brien C, Chen B, Xia Y, Zhou B, Loza MJ, Silkoff PE, Ge M, Thurmond RL . A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma . Annals of Allergy, Asthma & Immunology . 121 . 5 . 568–574 . 2018 . 10.1016/j.anai.2018.08.001 . 30102965 . 51972933 .
- Thurmond RL, Greenspan A, Radziszewski W, Xu XL, Miao Y, Chen B, Ge T, Zhou B, Baker DG, Pavlova D, Ritchlin CT, Tanaka Y, Takeuchi T, Smolen JS . Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies . The Journal of Rheumatology . 43 . 9 . 1637–1642 . September 2016 . 10.3899/jrheum.160164. 27422891 . 46885520 .
- Saravanan C, Bharti SK, Jaggi S, Singh SK . Histamine H4 receptor: a novel target for inflammation therapy . Mini Reviews in Medicinal Chemistry . 11 . 2 . 143–58 . February 2011 . 21222579 . 10.2174/138955711794519519 .
- Book: Thurmond RL, Venable J, Savall B, La D, Snook S, Dunford PJ, Edwards JP . Clinical Development of Histamine H4 Receptor Antagonists . Histamine and Histamine Receptors in Health and Disease . Handbook of Experimental Pharmacology . 2017 . 241 . 301–320 . 28233185 . 10.1007/164_2016_130 . 978-3-319-58192-7 .
- Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, Church MK, Saluja R . 6 . The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets . Frontiers in Immunology . 2018 . 9 . 1873 . 30150993 . 10.3389/fimmu.2018.01873 . 6099187 . free .